Aims: To evaluate therapy and dose adjustments in patients with congenital hypothyroidism (CH), longitudinally followed up until 16 years old, according to aetiology, Beclard’s nuclei presence, and thyroxine (T4) level at diagnosis. Methods:L-T4/kg/day and dose change ratio (CR) were assessed in 74 CH patients. Results: The dose was statistically larger in athyreosis than in dyshormonogenesis (1–10 and beyond 14 years) and in ectopy (2, 15, 16 years). The ectopic children required statistically larger L-T4/kg than the dyshormonogenetic ones (3–7 years). The L-T4/kg/day was increased, not statistically, in patients or with T4 <30 nmol/l or without Beclard’s nuclei at diagnosis. The CR progressively dropped after the 6th month at each attendance, without any difference in terms of aetiology, T4 level at diagnosis, or Beclard’s nuclei. The total CR was greater (significantly) in patients without Beclard’s nuclei, and (not significantly) in those with T4 <30 nmol/l at diagnosis or with agenesia. Conclusion: The L-T4 dose in CH is highly affected by the aetiology. The CR is higher in patients with delayed bone maturation at diagnosis. We suggest that these latter patients need blood tests more frequently to obtain a proper titration of the therapy.

Keywords:
Congenital hypothyroidism, L-thyroxine treatment, Aetiology, Severity, Dose change
1.
Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology: Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism. Horm Res 1999;52:49–52.
2.
Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK: Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006;117:2290–2303.
3.
Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G: Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 1996;81:222–227.
4.
Hanukoglu A, Perlman K, Shamis I, Brnjac L, Rovet J, Daneman D: Relationship of etiology to treatment in congenital hypothyroidism. J Clin Endocrinol Metab 2001;86:186–191.
5.
Song SI, Daneman D, Rovet J: The influence of etiology and treatment factors on intellectual outcome in congenital hypothyroidism. J Dev Behav Pediatr 2001;22:376–384.
6.
Moreno L, Ythier H, Loeuille GA, Lebecq MF, Dhondt JL, Farriaux JP: Growth and bone maturity during congenital hypothyroidism screened in the neonatal period. Apropos of 82 cases. Arch Fr Pediatr 1989;46:723–728.
7.
Touati G, Leger J, Czernichow P: Congenital hypothyroidism. Therapeutic strategy at the early stage of treatment. Arch Fr Pediatr 1991;48:461–465.
8.
Heyerdahl S, Kase BF, Stake G: Skeletal maturation during thyroxine treatment in children with congenital hypothyroidism. Acta Paediatr 1994;83:618–622.
9.
Dickerman Z, De Vries L: Prepubertal and pubertal growth, timing and duration of puberty and attained adult height in patients with congenital hypothyroidism (CH) detected by the neonatal screening programme for CH – a longitudinal study. Clin Endocrinol (Oxf) 1997;47:649–654.
10.
Kempers MJ, van Trotsenburg AS, van Tijn DA, Bakker E, Wiedijk BM, Endert E, de Vijlder JJ, Vulsma T: Disturbance of the fetal thyroid hormone state has long-term consequences for treatment of thyroidal and central congenital hypothyroidism. J Clin Endocrinol Metab 2005;90:4094–4100.
11.
Germak JA, Foley TP Jr: Longitudinal assessment of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1990;117:211–219.
12.
Grant DB: Growth in early treated congenital hypothyroidism. Arch Dis Child 1994;70:464–468.
13.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
14.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. California, Stanford Univesity Press, 1959.
15.
Traggiai C, Stanhope R: Disorders of pubertal development. Best Pract Res Clin Obstet Gynaecol 2003;17:41–56.
16.
Van Vliet G: Treatment of congenital hypothyroidism. Lancet 2001;358:86–87.
17.
Rovet JF: In search of the optimal therapy for congenital hypothyroidism. J Pediatr 2004;144:698–700.
18.
Salerno M, Militerni R, Di Maio S, Bravaccio C, Gasparini N, Tenore A: Intellectual outcome at 12 years of age in congenital hypothyroidism. Eur J Endocrinol 1999;141:105–110.
19.
Oerbeck B, Sundet K, Kase BF, Heyerdahl S: Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on intellectual, motor, and school-associated outcomes in young adults. Pediatrics 2003;112:923–930.
20.
Oerbeck B, Sundet K, Kase BF, Heyerdahl S: Congenital hypothyroidism: no adverse effects of high dose thyroxine treatment on adult memory, attention, and behaviour. Arch Dis Child 2005;90:132–137.
21.
Bongers-Schokking JJ, de Muinck Keizer-Schrama SM: Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism. J Pediatr 2005;147:768–774.
22.
Rovet JF: Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics 2005;115:e52–e57.
23.
Selva KA, Harper A, Downs A, Blasco PA, Lafranchi SH: Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. J Pediatr 2005;147:775–780.
24.
Salerno M, Micillo M, Di Maio S, Capalbo D, Ferri P, Lettiero T, Tenore A: Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol 2001;145:377–383.
25.
Adachi M, Asakura Y, Tachibana K: Final height and pubertal growth in Japanese patients with congenital hypothyroidism detected by neonatal screening. Acta Paediatr 2003;92:698–703.
26.
Bain P, Toublanc JE: Adult height in congenital hypothyroidism: prognostic factors and the importance of compliance with treatment. Horm Res 2002;58:136–142.
27.
Delvecchio M, Salerno M, Acquafreddda A, Zecchino C, Fico F, Manca F, Faienza MF, Cavallo L: Factors predicting final height in early treated congenital hypothyroid patients. Clin Endocrinol (Oxf) 2006;65:693–697.
28.
Garcia M, Calzada-Leon R, Perez J, Martinez MP, Gonzalez R, Perez M, Ruiz ML, Altamirano N: Longitudinal assessment of L-T4 therapy for congenital hypothyroidism: differences between athyreosis vs. ectopia and delayed vs normal bone age. J Pediatr Endocrinol Metab 2000;13:63–69.
29.
Wasniewska M, De Luca F, Cassio A, Oggiaro N, Gianino P, Delvecchio M, Aiazzi R, Stoppioni V, Lombardo F, Messina MF, Valenzise M, Arrigo T: In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment. Eur J Endocrinol 2003;149:1–6.
30.
Leger J, Larroque B, Norton J: Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study. Acta Paediatr 2001;90:1249–1256.
31.
Fisher DA: Clinical review 19: management of congenital hypothyroidism. J Clin Endocrinol Metab 1991;72:523–529.
32.
Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005;353:487–497.
33.
Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B: Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787–1795.
34.
Muir A, Daneman D, Daneman A, Ehrlich R: Thyroid scanning, ultrasound, and serum thyroglobulin in determining the origin of congenital hypothyroidism. Am J Dis Child 1988;142:214–216.
35.
De Bruyn R, Ng WK, Taylor J, Campbell F, Mitton SG, Dicks-Mireaux C, Grant DB: Neonatal hypothyroidism: comparison of radioisotope and ultrasound imaging in 54 cases. Acta Paediatr Scand 1990;79:1194–1198.
36.
Czernichow P, Schlumberger M, Pomarede R, Fragu P: Plasma thyroglobulin measurements help determine the type of thyroid defect in congenital hypothyroidism. J Clin Endocrinol Metab 1983;56:242–245.
37.
Mitchell ML, Hermos RJ: Measurement of thyroglobulin in newborn screening specimens from normal and hypothyroid infants. Clin Endocrinol (Oxf) 1995;42:523–527.
38.
Djemli A, Fillion M, Belgoudi J, Lambert R, Delvin EE, Schneider W, Van Vliet G: Twenty years later: a reevaluation of the contribution of plasma thyroglobulin to the diagnosis of thyroid dysgenesis in infants with congenital hypothyroidism. Clin Biochem 2004;37:818–822.
39.
Bakker B, Kempers MJ, De Vijlder JJ, Van Tijn DA, Wiedijk BM, Van Bruggen M, Vulsma T: Dynamics of the plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism. Clin Endocrinol (Oxf) 2002;57:529–537.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.